Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Chicago Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1114
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Chicago Medicine, Chicago, IL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Chicago Medicine, Chicago, IL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 853–864 of 1,114 matching trials with a site at University of Chicago Medicine, Chicago, IL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

NCT05257083
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Stichting European Myeloma Network
Network
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2040
U.S. locations
27
States / cities
Little Rock, Arkansas • Duarte, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Nov 5, 2026, 11:02 AM EST
Recruiting No phase listed Observational

Terumo Aortic Global Endovascular Registry

NCT04246463
Status at this site: Recruiting
View directory record Official record
Conditions
Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
Interventions
Thoracic, Abdominal, Custom Device, Illiac Artery
Device
Lead sponsor
Vascutek Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
17
States / cities
Long Beach, California • Aurora, Colorado • Colorado Springs, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Nov 5, 2026, 11:02 AM EST
Active, not recruiting Phase 2 Interventional

Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors

NCT03360890
Site status not listed — check the official record
View directory record Official record
Conditions
Thyroid Cancer, Salivary Gland Cancer
Interventions
Pembrolizumab, Docetaxel
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Nov 5, 2026, 11:02 AM EST
Active, not recruiting No phase listed Observational

A Study of miRNA 371 in Patients With Germ Cell Tumors

NCT04435756
Site status not listed — check the official record
View directory record Official record
Conditions
Germ Cell Tumor, Metachronous Malignant Neoplasm, Seminoma, Stage I Testicular Cancer AJCC v8, Stage IA Testicular Cancer AJCC v8, Stage IB Testicular Cancer AJCC v8, Stage IS Testicular Cancer AJCC v8
Interventions
Biomarker Analysis, Blood Product Collection
Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
412
States / cities
Gilbert, Arizona • Kingman, Arizona • Tucson, Arizona + 261 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Nov 5, 2026, 11:02 AM EST
Recruiting No phase listed Observational

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT06740383
Status at this site: Recruiting
View directory record Official record
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia, Delusional Disorder, Bipolar 1 Disorder, Schizoaffective Disorder, Psychosis Not Otherwise Specified, Early Psychosis
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 40 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Nov 5, 2026, 11:02 AM EST
Active, not recruiting Not applicable Interventional

Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life With HIV and Substance Use

NCT06682468
Site status not listed — check the official record
View directory record Official record
Conditions
Substance Use Disorders, HIV
Interventions
Population level patient portal based substance involvement screening, Usual Care Substance Use Involvement Screening
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Nov 5, 2026, 11:02 AM EST
Active, not recruiting Not applicable Interventional

A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer

NCT03561220
Site status not listed — check the official record
View directory record Official record
Conditions
Prostate Cancer
Interventions
Standard of Care IMRT (Photon), Standard of Care Proton Therapy, Proton Arm 1: Standard Proton Therapy, Proton Arm 2: Hypofractionated Proton Therapy
Radiation
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 85 Years · Male only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Loma Linda, California + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Nov 5, 2026, 11:02 AM EST
Active, not recruiting Phase 2 Interventional

Abemaciclib and Letrozole to Treat Endometrial Cancer

NCT04393285
Site status not listed — check the official record
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Abemaciclib, Letrozole
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
29
States / cities
Mobile, Alabama • Anchorage, Alaska • Greenwich, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Nov 5, 2026, 11:02 AM EST
Active, not recruiting Not applicable Interventional

Comparing Meniscal Repair Biologic Augmentation: Marrow Venting Procedure Versus PRP (MVP Trial)

NCT04775004
Site status not listed — check the official record
View directory record Official record
Conditions
Meniscal Tear
Interventions
Bone marrow venting procedure (BMVP), Platelet Rich Plasma (PRP)
Other
Lead sponsor
University of Chicago
Other
Eligibility
16 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Gainesville, Florida • Chicago, Illinois • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Nov 5, 2026, 11:02 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

NCT04262466
Site status not listed — check the official record
View directory record Official record
Conditions
Select Advanced Solid Tumors
Interventions
Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp, Brenetafusp and bevacizumab, Brenetafusp and kinase inhibitors
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Nov 5, 2026, 11:02 AM EST
Active, not recruiting Phase 4 Interventional

Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial

NCT04835506
Site status not listed — check the official record
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
Infliximab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
16 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
23
States / cities
New Haven, Connecticut • Miami, Florida • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Nov 5, 2026, 11:02 AM EST
Active, not recruiting Phase 3 Interventional Results available

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

NCT01349322
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Standard fractionation whole breast irradiation, Hypofractionated whole breast irradiation, Concurrent boost, Sequential boost
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
2,354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
386
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 304 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Nov 5, 2026, 11:02 AM EST

About this University of Chicago Medicine institution page

What this page lists
ClinicalTrials.gov records that list University of Chicago Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.